Late Effects after Allogeneic Hematopoietic Stem Cell Transplantation

Shahrukh Hashmi, Mark R. Litzow

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Worldwide, greater than 60 000 people undergo hematopoietic stem cell transplantation (HSCT) annually. Since the inception of HSCT in the treatment paradigm of human diseases approximately 50 years ago, substantial advances in HSCT techniques and supportive care have led to improvements in survival, but late effects of HSCT cause substantial morbidity and mortality. In the case of allogeneic HSCTs, immunosuppressive therapies and graft-versus-host disease are major contributors to these complications. The majority of the complications occur within a few years of allogeneic-HSCT; however the incidence of a few conditions (e.g., cardiovascular complications and secondary cancers) is highest at 6-10 years post-HSCT. Thus, these complications can be broadly divided into late effects (occurring after 6 months of HSCT) and very late effects (occurring after 5 years of HSCT). Management of specific late effects is discussed separately. The goals of this chapter include a comprehension of the basic concepts and identification of these effects.

Original languageEnglish (US)
Title of host publicationBlood and Marrow Transplantation Long Term Management
Subtitle of host publicationPrevention and Complications
Number of pages10
ISBN (Electronic)9781118473306
ISBN (Print)9781118473405
StatePublished - Sep 9 2013


  • Allogeneic
  • Cell
  • Effects
  • Graft-versus-host disease
  • Late
  • Quality
  • Secondary
  • Stem
  • Transplant

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Late Effects after Allogeneic Hematopoietic Stem Cell Transplantation'. Together they form a unique fingerprint.

Cite this